Policy Notices

• AHRQ Announces Interest in Health Services Research on Health System and Healthcare Professional Responsiveness to COVID-19
  (NOT-HS-22-010)
  Agency for Healthcare Research and Quality
  

• Notice of Change to NIHs Policy on Special Council Review of Research Applications
  (NOT-OD-22-049)
  National Institutes of Health
  

• FY 2022 Updated Guidance: Requirement for Instruction in the Responsible Conduct of Research
  (NOT-OD-22-055)
  National Institutes of Health
  

General Notices

• Notice to Clarify the Research Objectives of PAR-21-360 "Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)"
  (NOT-AG-22-015)
  National Institute on Aging
  

• RESCINDED - Request for Proposals (RFP) Notice: Blueprint MedTech (BPMT) Biocompatibility, Sterilization, and Animal Studies
  (NOT-DA-22-053)
  National Institute on Drug Abuse
  

• Notice of Availability of Application Information for RFA-TR-22-012 Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed)
  (NOT-TR-22-018)
  National Center for Advancing Translational Sciences
  

• Request for Information: Seeking Input for National Cancer Institute (NCI) on Advancing Research on Fusion Oncoproteins in Childhood Cancers
  (NOT-CA-22-032)
  National Cancer Institute
  

• Request for Information (RFI): Seeking Stakeholder Actionable Input to Improve Research on Health and Well-being for Asians, Native Hawaiians, and Pacific Islanders
  (NOT-CA-22-047)
  National Cancer Institute
  National Institute of General Medical Sciences
  National Institute on Minority Health and Health Disparities
  

Notice of Changes to Funding Opportunities

• Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
  (NOT-DA-21-079)
  National Institute on Drug Abuse
  

• Notice of Correction to Key Dates of PAR-21-185, "Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed)"
  (NOT-DC-22-007)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of NEI Participation in PAR-20-097, "Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)"
  (NOT-EY-22-013)
  National Eye Institute
  

• Notice of NHLBI Participation in NOT-MD-22-006, "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"
  (NOT-HL-22-012)
  National Heart, Lung, and Blood Institute
  

• Notice of Change to Key Dates for RFA-NS-21-010, "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"
  (NOT-NS-22-077)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to IC-Specific Interests for NINDS to PAR-21-155, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)"
  (NOT-NS-22-080)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Due Dates and Eligibility Criteria for NOT-NS-21-014, "Notice of Special Interest (NOSI): Availability of Administrative Supplements for BRAIN Initiative Awardees to Support Resource Dissemination"
  (NOT-NS-22-082)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction for PAR-22-088 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
  (NOT-OD-22-078)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) (U54 Clinical Trials Optional)
  (NOT-CA-22-052)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Limited Competition Administrative Supplement to the US Deprescribing Research Network to Support Feasibility Clinical Trials of Complementary and Integrative Approaches for Deprescribing Benzodiazepines
  (NOT-AT-22-012)
  National Center for Complementary and Integrative Health
  

• Notice of Special Interest (NOSI): Public Health Research on Cannabis
  (NOT-DA-22-003)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders
  (NOT-DA-22-056)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities
  (NOT-EY-22-004)
  National Eye Institute
  National Institute on Minority Health and Health Disparities
  

• Notice of Special Interest (NOSI): Research on Drowning Prevention
  (NOT-HD-21-048)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Minority Health and Health Disparities
  Office of Disease Prevention
  

• Notice of Special Interest (NOSI): Postmortem Pathology, Cellular, and Molecular Analyses to Determine the Significance of White Matter Lesions and other Imaging Findings of Presumed Vascular Origin During Life
  (NOT-NS-22-001)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  

Funding Opportunities

• Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
  (PAR-22-085)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
  (PAR-22-086)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional)
  (PAR-22-117)
  National Eye Institute
  Application Receipt Date(s): March 31, 2022
  
  

• Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)
  (RFA-AG-23-005)
  National Institute on Aging
  Application Receipt Date(s): July 01, 2022
  
  

• In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R01 Clinical Trial Not Allowed)
  (RFA-DE-23-004)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): June 14, 2022
  
  

• In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R21 Clinical Trial Not Allowed)
  (RFA-DE-23-005)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): June 14, 2022
  
  

• Retail Food Safety Regulatory Association Collaboration (U18) [Clinical Trial Not Allowed]
  (RFA-FD-22-008)
  Food and Drug Administration
  Application Receipt Date(s): April 22, 2022 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54, Basic Experimental Studies Involving Humans Allowed)
  (RFA-NS-22-019)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 24, 2022
  
  

• Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required)
  (RFA-NS-22-020)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 24, 2022
  
  

• Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional)
  (RFA-OD-22-005)
  Office of the Director, NIH
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Application Receipt Date(s): May 02, 2022
  
  

• Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional)
  (RFA-OD-22-006)
  Office of the Director, NIH
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Application Receipt Date(s): May 02, 2022
  
  

• Limited Competition: Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Optional)
  (RFA-RM-22-001)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): May 23, 2022
  
  

• NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)
  (RFA-RM-22-008)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 12, 2022